Stock scan­dals: Biotech in­cu­ba­tor Fortress pur­chased bro­ker­age firm to tout its own star­tups — Reuters

When an an­a­lyst touts a biotech stock, you hope he’s not get­ting paid by the com­pa­ny’s own­er, right? Well that’s ex­act­ly what Jonathan Aschoff …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.